Touat et al. demonstrated that over 98% of post-treatment HMP gliomas showed signature 11 and that exposing MMR-deficient cells to TMZ induces HMP with signature 11, suggesting that HMP and signature 11 represent MMR deficiency and TMZ resistance [6]. This evidence concerns the gene MRC1 and central nervous system cancer.